BioSpace News Archive

twoXAR Pharmaceuticals, a company that discovers drugs with AI, today announced the appointment of Mark Eller, Ph.D. as the Senior Vice President of Research and Development and Anjali Pandey, Ph.D. as the Senior Vice President of Nonclinical R&D and Chemistry. Both Dr. Eller and Dr. Pandey will report directly to Andrew A. Radin, CEO at twoXAR, and immediately assume direct responsibility for advancing 18 R&D programs across multiple therapeutic areas.

Remark Holdings, Inc. (NASDAQ: MARK), a diversified global technology company with leading artificial intelligence (“AI”) solutions and digital media properties, today announced a significant upgrade to its AI-based product offerings.

Innovative Forensic DNA announces the addition of Andrea Noyes to the firm as Investigative Genetic Genealogist and Co-Managing Director

A new survey of hospital C-suite leaders reveals 35% wish they had chosen a different EMR; more than half say they will seek out HIT solutions beyond the EMR for key needs

Sales Readiness Leader Honored for Enabling Businesses to Quickly and Easily Create Learning Content That Drives Sales Effectiveness and Results

Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the Cowen 40th Annual Healthcare Conference in Boston at 08:40 a.m. ET on Wednesday, March 4, 2020.

Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 140,352 shares of its common stock at a price of $14.25 per share, for aggregate gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market

Synergy Laboratories (Synergy) announced today that it has acquired Mobile, Alabama-based Pathology Laboratory Associates (PLA) for an undisclosed price

Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the fourth quarter and full year ended December 31, 2019. The Company reported total revenue of $37.8 million for the fourth quarter of 2019 and $123.9 million for the year ended December 31, 2019.

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced it received a response to the proposal it submitted to the U.S. Biomedical Advanced Research and Development Authority (BARDA) for funding a study designed to demonstrate the superiority of PLX-R18 therapy versus current standard of care in the treatment of Acute Radiation Syndrome (ARS)